Physician profile
Yumeng Li
NPI 1417319617
$32,805.65
in general payments reported to CMS, 2019-2025
36 companies · $16K in 2025
The $16K reported for 2025 was more than what 97% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $484 · 2021: $1,394 · 2022: $2,087 · 2023: $5,868 · 2024: $4,877 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,573.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,019.59 |
| Education | $279.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $15,966.84 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $2,197.18 | 2019-2025 | |
| Genzyme Corporation | $1,354.80 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,247.03 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $1,168.42 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,031.14 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $1,008.17 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $932.95 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $812.79 | 2022-2025 | |
| Leo Pharma INC. | $731.87 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $729.36 | 2021-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $686.29 | 2023-2025 | Zoryve |
| Ucb, INC. | $677.04 | 2022-2025 | Bimzelx |
| Dermavant Sciences, INC. | $606.79 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $565.76 | 2022-2023 | Tremfya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $525.84 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $317.03 | 2022-2025 | Dupixent |
| Celgene Corporation | $255.02 | 2019 | |
| Pfizer INC. | $246.21 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $243.36 | 2023 | Arazlo, Duobrii, Siliq |
| Amgen INC. | $233.90 | 2022-2025 | Otezla, Otezla, Enbrel |
| Organon LLC | $170.80 | 2025 | Vtama |
| Organogenesis INC. | $166.13 | 2023 | Puraply |
| Merz North America, INC. | $145.45 | 2019 | |
| Almirall LLC | $131.70 | 2022-2025 | Klisyri |
| Mallinckrodt Hospital Products INC. | $125.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.04 | 2023-2025 | Spevigo |
| Triad Life Sciences INC. | $101.25 | 2022 | |
| Biofrontera INC. | $82.45 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Revance Therapeutics, INC. | $48.56 | 2024 | Daxxify |
| Genentech USA, INC. | $24.64 | 2023 | Xolair |
| Smith+Nephew, INC. | $22.88 | 2024 | Grafix Pl |
| Kyowa Kirin, INC. | $20.44 | 2019 | |
| Integra Lifesciences Corporation | $18.77 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Verrica Pharmaceuticals INC. | $13.74 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yumeng Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.